Our goal is to develop more effective immunotherapies for acute myeloid leukemia (AML). We work at the interface of hematopoietic stem and progenitor cells (HSPCs) and T cells, as AML is a malignancy derived from HSPCs and still harbors many characteristics of its normal counterparts. We use chimeric antigen receptor (CAR) T cell therapy, in which T cells are genetically engineered to attack cancer, as this has achieved success in a variety of hematologic malignancies, such as B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia. We aim to extrapolate the success of CAR T cell therapy to AML.
Research keywords: CAR T cells; Hematopoietic stem cells; Cell and gene therapy
Basic information
| Pronouns: | She/Her/Hers |
| Mentoring statement: | Not provided. |
| Some former postdocs’ career outcomes: | Not provided. |
Postdoc openings within the next year
| Number of postdoc positions: | 1 |
| Postdoc eligibility: | U.S. Citizens or Permanent Residents Current Visa-Holding Trainees in the U.S. International Trainees Outside the U.S. |